Letter to the Editor | Published:

Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia

Leukemia volume 21, pages 23822384 (2007) | Download Citation


The basic leucine zipper (bZIP) transcription factor CCAAT/enhancer-binding protein-α (C/EBPα), encoded by the CEBPA gene, is essential for myeloid development.1 In acute myeloid leukemia (AML), interference with C/EBPα function may occur through several mechanisms.2 Mutations in the CEBPA coding region itself are observed in approximately 8% of AML. These mutations either involve N-terminal frameshift abnormalities, leading to increased translation of a 30 kDa isoform with dominant-negative properties, or in-frame insertions or deletions disrupting the bZIP domain located in the C-terminus.2 In many cases of AML, both types of mutations are found in the same leukemic cell, frequently involving both alleles, that is N-terminal mutation of one allele and C-terminal disruption of the other. In a previous gene expression profiling (GEP) study of 285 cases of de novo AML, two expression clusters were highly associated with CEBPA mutations.3 The majority of CEBPA mutant tumors in these clusters carried both an N-terminal and a bZIP mutation. Interestingly, in three cases only one of the two types of mutations was present, while a wild-type allele appeared to be absent. Here, we combined fluorescence in situ hybridization (FISH) experiments with single nucleotide polymorphism (SNP) array hybridization to investigate two potential mechanistic explanations for the existence of homozygous CEBPA mutations in these particular cases: deletion of the wild-type allele, or uniparental disomy (UPD) as a result of mitotic recombination.4

CEBPA mutational analysis by PCR and nucleotide sequencing has been described.3 These analyses revealed 17 mutant specimens, of which 3 carried homozygous mutations, in the cohort of 285 cases of AML.3 Two leukemias harbored homozygous mutations in the CEBPA bZIP region, whereas in the other case the mutation was found in the N-terminus (Table 1).

Table 1: Characteristics of AML cases with homozygous CEBPA mutations

To investigate whether homozygous CEBPA mutations correlated with loss of the wild-type allele through deletion, we carried out dual color FISH using three BAC clones RP11-270I13, RP11-547I3 and RP11-1150B17; Supplementary Figure 1) located on 19q13.11 as probes. In all three specimens with homozygous mutations, signals for both homologues were detected in more than 95% of cells (data not shown), excluding deletion as the underlying mechanism for homozygosity.

We next used Affymetrix (Santa Clara, CA, USA) Mapping 250K NspI SNP arrays to assess the CEBPA locus in more detail. We investigated 14/17 AML cases with CEBPA mutations, including the 3 AMLs with homozygous CEBPA abnormalities. Data were imported into SNPExpress, a software tool developed in our department (Sanders et al., submitted). Mapping of probe sets to genes was done according to data provided by Affymetrix. On the arrays used, none of the probe sets mapped directly to the CEBPA gene. Probe set SNP_A-2236362, associated with neighboring gene CEBPG (Supplementary Figure 1), was therefore used as a marker for the CEBPA locus. We first determined copy numbers of chromosome 19q13.11 for each patient based on these SNP arrays using dChipSNP. This analysis confirmed the results obtained by FISH, as the calculated copy number of the region containing the CEBPA gene fluctuated closely around 2 in all 14 leukemias (Figure 1). We subsequently assessed potential regions of loss of heterozygosity (LOH) using a hidden Markov model. Strikingly, we found extensive regions of LOH of chromosome 19, including the CEBPA locus, in the three samples with homozygous CEBPA aberrations. In all three leukemias, LOH included the majority of the 19q arm, and stretched until the telomeres (Figure 1). In contrast, no LOH of the CEBPA locus was apparent in the 11 samples carrying heterozygous CEBPA mutations. These results demonstrate that copy number neutral LOH of 19q13.11 is associated with homozygous CEBPA mutations, which is indicative of UPD through mitotic recombination in this region.

Figure 1
Figure 1

Copy number neutral loss of heterozygosity (LOH) in three cases of acute myeloid leukemia (AML) with homozygous CEBPA mutations. Affymetrix Mapping 250K NspI arrays were used to investigate chromosomal copy numbers and genotypes of AML cases with CEBPA mutations. Six cases are shown in this figure: patients #1, #2 and #3 harbor homozygous CEBPA mutations, and cases #4, #5 and #6 carry heterozygous CEBPA mutations. A region on chromosome 19q13.11, including the CEBPA locus (CEBPA), is depicted at larger magnification. For each individual single nucleotide polymorphism (SNP) in this region, copy number was calculated, and is indicated as deflection from the green midline, which represents the presence of two chromosomes (deflection to the left indicates lower copy number, deflection to the right indicates higher copy number). Genotypes for each SNP are color-coded: homozygous AA (red) or BB (yellow), and heterozygous AB (blue). A hidden Markov model was employed to assess potential LOH, and revealed LOH of the region shown in patients #1, #2 and #3, illustrated by the fact that the large majority of calls is homozygous. The infrequent remaining heterozygous (blue) signals are considered false calls according to this model. The extents of the regions of LOH are indicated as red bars next to the schematic representation of chromosome 19 (‘region of LOH’) for each of these three cases.

UPD has recently emerged as a mechanism involved in malignancy, including AML.5, 6, 7 Genome-wide studies using high-resolution SNP arrays have indicated that approximately 20% of AMLs with a normal karyotype show either interstitial or terminal UPD.4, 5, 6, 7, 8 Acquired UPD is associated with removal of wild-type alleles of genes commonly mutated in AML, including RUNX1, FLT3 and WT1.5 Previously, a single case of AML with a homozygous CEBPA bZIP mutation and UPD has been reported.5 Our results imply that terminal UPD involving mutant CEBPA alleles is a recurrent mechanism.

In a previous unsupervised GEP study, the three AMLs described here clustered together with other CEBPA mutant AML cases in two distinct expression clusters.3 The common finding in these clusters was that the CEBPA mutant AMLs carried mutations in both alleles and consequently did not express wild-type CEBPA. Although the functional implication of replacement of wild-type CEBPA remains elusive, its absence, resulting either from biallelic mutations or from homozygous mutations, seems to be critical for leukemic development of those cases. It is currently unclear whether homozygous CEBPA mutations have a specific differential significance as opposed to biallelic heterozygous aberrations. It will be interesting to investigate whether loss of wild-type alleles of additional genes on chromosome 19 plays a role in leukemogenesis in these cases.

Another interesting question is whether the initially mutated allele in the AMLs with homozygous CEBPA mutations was acquired, or was already present in the germline. This would particularly be of interest because familial N-terminal mutations have been described. Unfortunately, we were not able to address this issue, as normal or remission control material was not available for any of the three patients.

In conclusion, we describe the association of homozygous CEBPA mutations in three cases of AML with mitotic recombination involving the CEBPA locus. Our findings are consistent with recent reports suggesting the frequent occurrence of UPD in AML, and imply that this mechanism is responsible for a substantial proportion of cases with homozygous CEBPA aberrations.




  1. 1.

    , , , , , . Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569–574.

  2. 2.

    . C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4: 394–400.

  3. 3.

    , , , , , et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617–1628.

  4. 4.

    , , , , , et al. A role for mitotic recombination in leukemogenesis. Adv Enzyme Regul 2006; 46: 90–97.

  5. 5.

    , , , , , et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005; 65: 9152–9154.

  6. 6.

    , , , , , . Frequent loss of heterozygosity without loss of genetic material in acute myeloid leukemia with a normal karyotype. Genes Chromosomes Cancer 2005; 44: 334–337.

  7. 7.

    , , , , , et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005; 65: 375–378.

  8. 8.

    , , , , , et al. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 2006; 108: 1684–1689.

Download references


We thank Roel Verhaak for assistance in data analysis. This work was supported by a grant from the Dutch Cancer Society ‘Koningin Wilhelmina Fonds’.

Author information


  1. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands

    • B J Wouters
    • , M A Sanders
    • , S Lugthart
    • , W M C Geertsma-Kleinekoort
    • , B Löwenberg
    • , P J M Valk
    •  & R Delwel
  2. Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands

    • E van Drunen
    •  & H B Beverloo


  1. Search for B J Wouters in:

  2. Search for M A Sanders in:

  3. Search for S Lugthart in:

  4. Search for W M C Geertsma-Kleinekoort in:

  5. Search for E van Drunen in:

  6. Search for H B Beverloo in:

  7. Search for B Löwenberg in:

  8. Search for P J M Valk in:

  9. Search for R Delwel in:

Corresponding author

Correspondence to R Delwel.

Supplementary information

Word documents

  1. 1.

    Supplementary Figure 1

About this article

Publication history




Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Further reading